Savara Inc
SVRA5.300USD
+0.140+2.71%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
916.11MMarket Cap
LossP/E TTM
More Details of Savara Inc Company
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Savara Inc Info
Ticker SymbolSVRA
Company nameSavara Inc
IPO dateJun 25, 2001
CEOPauls (Matthew)
Number of employees59
Security typeOrdinary Share
Fiscal year-endJun 25
Address6836 Bee Cave Road
CityAUSTIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78746
Phone151285113796
Websitehttps://savarapharma.com/
Ticker SymbolSVRA
IPO dateJun 25, 2001
CEOPauls (Matthew)
Company Executives of Savara Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
+20000.00%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
132.03K
-62960.00%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+20000.00%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
33.98K
-67760.00%
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Independent Director
Independent Director
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Director
Independent Director
--
--
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Dr. Joseph S. (Joe) Mccracken, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David A. Ramsay
Mr. David A. Ramsay
Independent Director
Independent Director
2.49M
+20000.00%
Ms. Anne Erickson
Ms. Anne Erickson
Chief Business Officer
Chief Business Officer
132.03K
-62960.00%
Mr. Braden Parker
Mr. Braden Parker
Chief Commercial Officer
Chief Commercial Officer
105.00K
+20000.00%
Mr. Robert Matthew (Rob) Lutz
Mr. Robert Matthew (Rob) Lutz
Chief Operating Officer
Chief Operating Officer
33.98K
-67760.00%
Mr. Matthew (Matt) Pauls, J.D.
Mr. Matthew (Matt) Pauls, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. David L. Lowrance, CPA
Mr. David L. Lowrance, CPA
Chief Financial and Administrative Officer, Secretary
Chief Financial and Administrative Officer, Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
12.03%
Bain Capital Life Sciences Investors, LLC
8.65%
Deerfield Management Company, L.P.
6.67%
VR Adviser, LLC
6.23%
TCG Crossover Management, LLC
6.08%
Other
60.35%
Shareholders
Shareholders
Proportion
New Enterprise Associates (NEA)
12.03%
Bain Capital Life Sciences Investors, LLC
8.65%
Deerfield Management Company, L.P.
6.67%
VR Adviser, LLC
6.23%
TCG Crossover Management, LLC
6.08%
Other
60.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.38%
Venture Capital
19.47%
Hedge Fund
17.41%
Investment Advisor/Hedge Fund
13.35%
Private Equity
5.63%
Individual Investor
2.15%
Research Firm
1.54%
Bank and Trust
0.11%
Pension Fund
0.02%
Other
9.92%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
294
181.72M
89.31%
-12.25M
2025Q3
286
169.85M
86.94%
-21.45M
2025Q2
295
181.81M
105.19%
-8.48M
2025Q1
306
176.74M
102.29%
-9.64M
2024Q4
294
173.80M
101.27%
-5.45M
2024Q3
274
169.68M
103.28%
+3.87M
2024Q2
257
157.29M
95.89%
+28.15M
2024Q1
230
131.01M
94.21%
-92.17K
2023Q4
197
123.19M
91.03%
-2.15M
2023Q3
177
120.11M
89.27%
+14.67M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
New Enterprise Associates (NEA)
24.47M
12.03%
--
--
Nov 12, 2025
Bain Capital Life Sciences Investors, LLC
17.60M
8.65%
--
--
Sep 30, 2025
Deerfield Management Company, L.P.
13.57M
6.67%
+5.61M
+70.38%
Oct 30, 2025
VR Adviser, LLC
12.68M
6.23%
+3.80M
+42.74%
Sep 30, 2025
TCG Crossover Management, LLC
12.36M
6.08%
--
--
Sep 30, 2025
Frazier Life Sciences Management, L.P.
11.46M
5.63%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
8.31M
4.09%
-121.57K
-1.44%
Sep 30, 2025
Nantahala Capital Management, LLC
8.78M
4.31%
+450.00K
+5.41%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
7.60M
3.74%
-943.37K
-11.04%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.24%
Texas Capital Texas Small Cap Equity Index ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.13%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.07%
Texas Capital Texas Equity Index ETF
0.05%
iShares Biotechnology ETF
0.03%
ProShares Hedge Replication ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.03%
iShares Russell 2000 Growth ETF
0.03%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.24%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.24%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
iShares Micro-Cap ETF
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
Texas Capital Texas Equity Index ETF
Proportion0.05%
iShares Biotechnology ETF
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.03%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
